Stoke Therapeutics, Inc. (STOK) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Stoke Therapeutics is a clinical-stage biotechnology company focused on restoring protein expression using RNA-based medicines, specifically its proprietary TANGO platform. The company's lead candidates are zorevunersen (STK-001) for Dravet syndrome and STK-002 for Autosomal Dominant Optic Atrophy (ADOA). The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Revenue | $4,831 | $(2,481) | $9,048 | $2,671 |
| Net Loss | $(25,695) | $(30,654) | $(52,069) | $(53,199) |
| Net Loss Per Share | $(0.46) | $(0.69) | $(1.02) | $(1.23) |
| Operating Expenses | $34,173 | $30,781 | $66,762 | $60,624 |
| Cash & Cash Equivalents | $193,476 | $192,060 | $193,476 | $192,060 |
| Marketable Securities | $88,506 | $9,952 | $88,506 | $9,952 |
| Total Liquidity | $281,982 | $202,012 | $281,982 | $202,012 |
Note: Revenue is derived from collaboration agreements, primarily with Acadia Pharmaceuticals. The company has no product sales revenue.
Material Changes vs. Prior Period
- Revenue Increase: Revenue for the three months ended June 30, 2024, was $4.8 million, a significant increase from a negative $2.5 million in the same period in 2023. This is attributed to the recognition of revenue from the Acadia Pharmaceuticals collaboration agreement.
- Reduced Net Loss: Net loss decreased by approximately $5.0 million quarter-over-quarter (from $30.7M to $25.7M) and by $1.1 million year-to-date (from $53.2M to $52.1M), driven by higher revenue and increased interest income.
- Capital Raise: In April 2024, the company completed a follow-on offering, raising net proceeds of approximately $119.9 million. This significantly bolstered cash reserves compared to the prior year.
- Investing Activities: The company invested heavily in marketable securities, purchasing $88.2 million in the first half of 2024, compared to net sales of securities in the prior year period.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects current cash, cash equivalents, and marketable securities ($282.0 million) to fund operations and capital expenditures through at least the end of 2025.
- Clinical Updates:
- Zorevunersen: The FDA removed a partial clinical hold on higher doses in August 2024. The company is on track to provide a regulatory update on Phase 3 registrational plans in the second half of 2024.
- STK-002: The Phase 1 OSPREY study for ADOA is expected to start later in 2024.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional capital to fund future development, regulatory approval delays, and the company's history of operating losses. The company anticipates continued net losses for the foreseeable future.
- Collaboration: The company relies on a collaboration with Acadia Pharmaceuticals, which includes potential milestone payments up to $907.5 million and tiered royalties, though these are contingent on future achievements.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the $282 million liquidity figure and the assumption that it will sustain operations through the end of 2025 given potential increases in R&D spend.
- Revenue Recognition: Review the specific terms of the Acadia Pharmaceuticals agreement to understand the sustainability of the revenue recognized in Q2 2024 versus future periods.
- Clinical Hold Status: Confirm the current status of the FDA clinical hold removal for zorevunersen and the timeline for the Phase 3 regulatory update.
- Dilution: Assess the impact of the April 2024 follow-on offering and the at-the-market sales agreement on existing shareholder dilution.
- Expense Trends: Monitor the trajectory of Research and Development expenses, which increased to $43.5 million YTD 2024, to ensure alignment with the projected cash runway.